Bio-Techne Corporation (TECH)
Largest Insider Buys in Sector
TECH Stock Price History Chart
TECH Stock Performance
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and …
Insider Activity of Bio-Techne Corporation
Over the last 12 months, insiders at Bio-Techne Corporation have bought $0 and sold $2.29M worth of Bio-Techne Corporation stock.
On average, over the past 5 years, insiders at Bio-Techne Corporation have bought $105,765 and sold $42.88M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 300 shares for transaction amount of $105,765 was made by BAUMGARTNER ROBERT V () on 2022‑05‑10.
List of Insider Buy and Sell Transactions, Bio-Techne Corporation
| 2024-08-08 | Sale | director | 16,000 0.0099% | $72.10 | $1.15M | +0.52% | ||
| 2024-05-14 | Sale | director | 4,000 0.0025% | $83.84 | $335,377 | -10.74% | ||
| 2024-03-07 | Sale | director | 10,400 0.0066% | $76.98 | $800,627 | -3.73% | ||
| 2023-08-30 | Sale | director | 8,939 0.0057% | $80.32 | $717,959 | -10.75% | ||
| 2023-07-21 | Sale | Chief Executive Officer | 80,000 0.0503% | $88.36 | $7.07M | -19.60% | ||
| 2023-06-07 | Sale | Chief Executive Officer | 322 0.0002% | $83.00 | $26,726 | -12.11% | ||
| 2022-12-08 | Sale | SVP - GENERAL COUNSEL | 7,450 0.0048% | $82.12 | $611,810 | -4.32% | ||
| 2022-08-10 | Sale | 100 0.0003% | $374.89 | $37,490 | -14.58% | |||
| 2022-06-07 | Sale | CHIEF EXECUTIVE OFFICER | 5,104 0.013% | $365.00 | $1.86M | -10.27% | ||
| 2022-06-07 | Sale | 1,000 0.0025% | $364.31 | $364,310 | -10.27% | |||
| 2022-05-10 | 300 0.0008% | $352.55 | $105,765 | -6.24% | ||||
| 2021-11-19 | Sale | Pres. Diagnostics & Genom | 500 0.0013% | $505.38 | $252,689 | -25.89% | ||
| 2021-11-12 | Sale | President-Protein Sciences | 27,159 0.069% | $504.00 | $13.69M | -25.51% | ||
| 2021-11-02 | Sale | Chief Financial Officer | 200 0.0005% | $525.10 | $105,020 | -24.34% | ||
| 2021-11-01 | Sale | Chief Financial Officer | 8,822 0.0225% | $526.52 | $4.64M | -27.41% | ||
| 2021-10-29 | Sale | Chief Financial Officer | 662 0.0017% | $525.23 | $347,704 | -27.12% | ||
| 2021-10-28 | Sale | Chief Financial Officer | 100 0.0003% | $525.18 | $52,518 | -25.88% | ||
| 2021-09-22 | Sale | Pres. Diagnostics & Genom | 822 0.0021% | $529.04 | $434,871 | -24.44% | ||
| 2021-09-07 | Sale | director | 8,000 0.0203% | $509.98 | $4.08M | -19.57% | ||
| 2021-09-02 | Sale | Chief Financial Officer | 10,000 0.0254% | $507.22 | $5.07M | -18.94% |
Insider Historical Profitability
| BAUMGARTNER ROBERT V | director | 43401 0.0273% | $71.19 | 6 | 15 | +12.2% |
| Kummeth Charles R. | Chief Executive Officer | 1258766 0.7922% | $71.19 | 1 | 21 | +18.28% |
| OCONNELL HOWARD V | director | 70000 0.0441% | $71.19 | 1 | 15 | +32.95% |
Institutional Investor Ownership
| The Vanguard Group | $1.29B | 11.6 | 18.27M | +0.24% | +$3.11M | 0.02 | |
| BlackRock | $1.25B | 11.26 | 17.75M | -2.14% | -$27.31M | 0.03 | |
| State Street | $448.31M | 4.04 | 6.37M | +0.64% | +$2.87M | 0.02 | |
| T. Rowe Price | $404.47M | 3.65 | 5.75M | +92.11% | +$193.93M | 0.05 | |
| Bamco | $351.82M | 3.17 | 5M | -6.61% | -$24.9M | 0.94 |